Lapatinib, neratinib and rucaparib are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications.
- Lapatinib (Tykerb®, Tyverb®) is a HER2 inhibitor and is indicated for the treatment of breast cancer
- Neratinib (Nerlynx®) is a HER1/2/3 inhibitor and is indicated for the treatment of breast cancer
- Rucaparib (Rubraca®) is a PARP inhibitor and is indicated for the treatment of epithelial ovarian, fallopian tube and primary peritoneal cancer
